Agenda: Patient Enrollment Innovative Trends Using a Liquid Biopsy
Wednesday February 9, 2022 | 12.30pm – 3.30pm PT | 3.30pm – 6.30pm ET
12:30 pm Hanson Wade & Guardant Health Opening Remarks
Clinical Trends Using MRD in Bladder, Lung & Breast
Synopsis
The objective of this session is to review and discuss the latest trends in Bladder, Lung and Breast oncology trials and innovative MRD use cases to solve outstanding clinical challenges in early-stage disease. Our expert speaker and panelists will discuss unmet clinical and diagnostic needs in the adjuvant and neoadjuvant settings, as well as the potential of LBx to provide a solution.
12:35 pm Presentation
1:00 pm Panel Discussion
Guardant Health Clinical Roll-out of MRD Monitoring
1:35 pm Presentation
2:00 pm Break
Copy Number Alterations: Clinical Unmet Needs & LBx Impact
Synopsis
This session will delve into the specific challenges that late-stage cancer patients are facing with emerging copy number alterations and in the innovative diagnostic solutions to inform clinical decisions. For instance, our panel will discuss mechanisms of resistance (e.g. CCNE1, ERBB2, MET) as well as the corresponding biomarkerinformed treatments. The panelists will also touch on the underlying technological (focal amplification vs. aneuploidy) and clinical challenges for a prospective trial roll-out and LBx considerations.